Autor segons l'article: Gutierrez, Maria Del Mar; Mur, Isabel; Mateo, Maria Gracia; Vidal, Francesc; Domingo, Pere;
Departament: Medicina i Cirurgia
Autor/s de la URV: Vidal Marsal, Francisco
Paraules clau: Tdf Sars-cov-2 Risk factor Remdesivir Randomized controlled trial (topic) R Prevalence Nonhuman Mortality rate Lpv/r Lpv Janus kinase inhibitor Interferon Infliximab Immunomodulating agent Il-6 antagonists Hydroxychloroquine Humans Human immunodeficiency virus infection Human immunodeficiency virus infected patient Human Hiv infections Ftc Drv Drug mechanism Disease severity Dexamethasone Cytokine receptor antagonist Covid-19 Corticosteroid Coronavirus disease 2019 Complication Clinical outcome Chloroquine Cart Bevacizumab Azithromycin Article Antivirus agent Antiviral therapy Antiviral agents Antiretrovirus agent Antiretroviral therapy Anticoagulant therapy Anti-sars-cov-2 agent Anti-retroviral agents Anakinra Adalimumab
Resum: Introduction
When coronavirus infectious disease-2019 (COVID-19) blew up, ill-fated auguries on the collision between COVID-19 and the human immunodeficiency virus (HIV) epidemics loomed.
Areas covered
Data from observational studies suggest similar incidence attacks of SARS-CoV-2 infection in people living with HIV (PLWH) and HIV-uninfected populations. The mortality rate of COVID-19 is similar in both populations too. The authors discuss the role of combination antiretroviral therapy (cART) in preventing infection or reducing COVID-19 severity. They also discuss the pharmacological interventions for COVID-19 in PLWH.
Expert opinion
Management of COVID-19 in PLWH is no different from the general population. It should be based on careful supportive care, emphasizing lung-protective ventilation, and wise pharmacological interventions. The antiviral drug remdesivir and dexamethasone are the only pharmacological interventions with clinical benefit for COVID-19, whereas anticoagulation may prevent thrombotic complications. The experience with using these drugs in PLWH is limited, which prevents from rendering well-founded conclusions. Until more data on COVID-19 in PLWH become available, the best weapons within our reach are sound supportive care and sensible use of RDV and dexamethasone, bearing in mind the potential for drug-drug interactions of most corticosteroids and antiretroviral drugs.
Àrees temàtiques: Saúde coletiva Pharmacology (medical) Pharmacology & pharmacy Pharmacology Medicine (miscellaneous) Medicina iii Medicina ii Medicina i General medicine Farmacia Ciências biológicas ii
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: francesc.vidal@urv.cat
Identificador de l'autor: 0000-0002-6692-6186
Data d'alta del registre: 2024-07-27
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Expert Opinion On Pharmacotherapy. 22 (9): 1127-1141
Referència de l'ítem segons les normes APA: Gutierrez, Maria Del Mar; Mur, Isabel; Mateo, Maria Gracia; Vidal, Francesc; Domingo, Pere; (2021). Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH). Expert Opinion On Pharmacotherapy, 22(9), 1127-1141. DOI: 10.1080/14656566.2021.1887140
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2021
Tipus de publicació: Journal Publications
Repositori URV